The partners will use Inify's AI platform to identify potentially cancerous regions in prostate cancer biopsy images within Karolinska's ProMort program.

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit® CRC v21, a next-generation AI solution.